KMDA Живые сигналы | Максимизируйте прибыль с Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 апр. 2024 @ 23:00):

Stats
Объем за сегодня	5 433.00
Средний объем	21 525.00
Рыночная капитализация	295.99M
EPS	$0 ( 2024-03-06 )
Дата следующего отчета о доходах	( $0.0600 ) 2024-05-22
Last Dividend	$0.00600 ( 2013-06-13 )
Next Dividend	$0 ( N/A )
P/E	34.33
ATR14	$0.0300 (0.58%)

Kamada Ltd Корреляция

10 Самые положительные корреляции
GAINL	0.895
RMRM	0.88

10 Самые отрицательные корреляции

Вы знали?

Корреляция - это статистический показатель, описывающий связь между двумя переменными. Он изменяется от -1 до 1, где -1 указывает на идеальную отрицательную корреляцию (при увеличении одной переменной другая уменьшается), 1 указывает на идеальную положительную корреляцию (при увеличении одной переменной другая увеличивается), а 0 указывает на отсутствие корреляции (между переменными нет связи).

Корреляцию можно использовать для анализа связи между любыми двумя переменными, не только акциями. Она широко используется в таких областях, как финансы, экономика, психология и т. д.

Kamada Ltd Финансовые показатели

Annual	2023
Выручка:	$144.76M
Валовая прибыль:	$52.59M (36.33 %)
EPS:	$0.170

FY	2023
Выручка:	$144.76M
Валовая прибыль:	$52.59M (36.33 %)
EPS:	$0.170

FY	2022
Выручка:	$129.34M
Валовая прибыль:	$46.70M (36.11 %)
EPS:	$-0.0518

FY	2021
Выручка:	$103.64M
Валовая прибыль:	$30.33M (29.26 %)
EPS:	$-0.0500

Financial Reports:

No articles found.

Kamada Ltd Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Kamada Ltd Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.03 - good (90.33%) | Divividend Growth Potential Score: 2.37 - No dividend growth expected in the near future

Information

First Dividend	$0.00600	2013-06-13
Last Dividend	$0.00600	2013-06-13
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.00600	--
Avg. Dividend % Per Year	0.00%	--
Score	1.72	--
Div. Sustainability Score	9.03
Div.Growth Potential Score	2.37
Div. Directional Score	5.70	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

1.72

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield
2013	$0.00600	0.06%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0574	1.500	8.85	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0235	1.200	9.22	10.00	[0 - 0.3]
returnOnEquityTTM	0.0398	1.500	-0.669	-1.003	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.43	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.554	0.800	5.56	4.45	[0.8 - 2.5]
cashRatioTTM	1.122	1.500	4.88	7.32	[0.2 - 2]
debtRatioTTM	0.0250	-1.500	9.58	-10.00	[0 - 0.6]
interestCoverageTTM	6.53	1.000	8.69	8.69	[3 - 30]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.0139	-0.0278	[0 - 20]
debtEquityRatioTTM	0.0364	-1.500	9.85	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.389	1.000	6.84	6.84	[0.2 - 0.8]
operatingProfitMarginTTM	0.0587	1.000	-0.827	-0.827	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.496	1.000	8.36	8.36	[0.2 - 2]
assetTurnoverTTM	0.410	0.800	-0.598	-0.478	[0.5 - 2]
Total Score				9.03

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	35.73	1.000	6.49	0	[1 - 100]
returnOnEquityTTM	0.0398	2.50	-0.430	-1.003	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.0278	2.00	-0.00928	-0.0278	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.0760	2.00	9.97	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.633	1.500	9.12	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0302	1.000	-1.744	0	[0.1 - 0.5]
Total Score				2.37

Kamada Ltd

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis ; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. Kamada Ltd. has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.